Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

False-positive screening results in the Finnish prostate cancer screening trial.

Kilpeläinen TP, Tammela TL, Määttänen L, Kujala P, Stenman UH, Ala-Opas M, Murtola TJ, Auvinen A.

Br J Cancer. 2010 Feb 2;102(3):469-74. doi: 10.1038/sj.bjc.6605512. Epub 2010 Jan 5.

2.

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force.

Ann Intern Med. 2008 Aug 5;149(3):192-9. Review.

PMID:
18678846
3.
4.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
5.

Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.

Ito K.

Int J Urol. 2009 May;16(5):458-64. doi: 10.1111/j.1442-2042.2009.02293.x. Epub 2009 Apr 1. Review.

7.

[PSA-based early detection of prostate cancer].

Luboldt H, Rübben H.

Urologe A. 2000 Jan;39(1):22-6. Review. German.

PMID:
10663192
8.

Should prostate-specific antigen screening be offered to asymptomatic men?

van Vugt HA, Bangma CH, Roobol MJ.

Expert Rev Anticancer Ther. 2010 Jul;10(7):1043-53. doi: 10.1586/era.10.64. Review.

PMID:
20645694
9.

[Prostate cancer and prostate specific antigen screening].

Camici M.

Minerva Med. 2004 Feb;95(1):25-34. Review. Italian.

PMID:
15041924
10.
11.

The case for prostate cancer screening.

Andriole GL.

Semin Urol. 1993 May;11(2):50-3. Review.

PMID:
7689738
12.

The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.

Roddam AW, Hamdy FC, Allen NE, Price CP; UK Prostate Cancer Risk Management Programme.

BJU Int. 2007 Sep;100(3):514-7. Epub 2007 Jun 2. Review.

13.

Screening for prostate cancer with prostate-specific antigen: beware the biases.

Bunting PS.

Clin Chim Acta. 2002 Jan;315(1-2):71-97. Review.

PMID:
11728412
14.

[Multiparametric MRI for prostate cancer screening].

Hoeks CM, Fütterer JJ, Somford DM, van Oort IM, Huisman H, Barentsz JO.

Ned Tijdschr Geneeskd. 2009;153:B487. Review. Dutch.

PMID:
20003566
15.
16.

Prostate cancer. When to offer screening in the primary care setting.

Gambert SR.

Geriatrics. 2001 Jan;56(1):22-6, 29-31. Review.

PMID:
11196336
17.

Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.

Pienta KJ.

Urology. 2009 May;73(5 Suppl):S11-20. doi: 10.1016/j.urology.2009.02.016. Review. Erratum in: Urology. 2010 Sep;76(3):771.

PMID:
19375622
18.
19.

PSA Screening for Prostate Cancer.

Quaas J.

Am Fam Physician. 2015 May 1;91(9):Online. Review. No abstract available.

20.

[Problems in PSA screening--distinction from false positives].

Fukumori T, Kanayama HO.

Nihon Rinsho. 2011 Jun;69 Suppl 5:259-63. Review. Japanese. No abstract available.

PMID:
22207982

Supplemental Content

Support Center